Notable Analyst Rating Changes 7/28: (ABCO) (AXTI) (BLDP) Upgraded; (DNKN) (ASH) (TERP) Downgraded
Get Alerts ABCO Hot Sheet
Join SI Premium – FREE
Craig-Hallum raises Advisory Board Company (Nasdaq: ABCO) from Hold to Buy with a price target of $47.
Needham & Company upgrades AXT, Inc. (Nasdaq: AXTI) from Hold to Buy with a price target of $5.50. Click Here for more color.
FBR Capital moves Ballard Power Systems (Nasdaq: BLDP) from Market Perform to Outperform and moves its price target from $1.50 to $3. Click Here for more color.
Argus lifts US Steel (NYSE: X) from Hold to Buy with a price target of $30. Click Here for more color.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES
CLSA downgrades Dunkin' Brands (Nasdaq: DNKN) from Outperform to Underperform.
Credit Suisse drops Ashland Inc. (NYSE: ASH) from Outperform to Neutral and moves its price target from $122 to $119. Click Here for more color.
Avondale Partners reduces TerraForm Power (Nasdaq: TERP) from Market Outperform to Market Perform and moves its price target from $18 to $12.50.
Craig-Hallum lowers RTI Biologics (Nasdaq: RTIX) from Buy to Hold and cuts its price target from $6 to $4.
For daily real-time Downgrades go to http://www.streetinsider.com/downgrades
NEW COVERAGE
Roth Capital resumes Stamps.com (Nasdaq: STMP) with a Buy rating.
Pacific Crest initiates Mellanox Technologies (Nasdaq: MLNX) with a Sector Weight rating.
Johnson Rice assumes coverage on Newfield Exploration (NYSE: NFX) with a Buy rating.
Citi starts Platform Specialty Products (NYSE: PAH) with a Buy rating.
For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage
Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Applied Blockchain Inc (APLD) PT Lowered to $13 at Needham
- SharkNinja (SN) selling shareholders to offer ~4.7M shares
- Immuneering Corporation (IMRX) PT Lowered to $15 at Needham, 'to reflect a lower probability of meaningful efficacy as monotherapy'
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Credit Suisse, Citi, Needham & Company, Roth Capital, Johnson Rice, Avondale Partners, Argus, Pacific Crest Securities, Notable Analyst Rating ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!